id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-343273-zaaraiy7	Hensley, Lisa E.	Interferon-β 1a and SARS Coronavirus Replication	2004-02-17		.txt	text/plain	1009	58	49	Here, we report that recombinant human interferon (IFN)-β 1a potently inhibits SARS coronavirus replication in vitro. The IFN-β 1a preparation employed in this study was selected because it is currently used as part of the most effective treatment regimen for relapsing forms of multiple sclerosis (8) , and more importantly, because it was shown to have antiviral activity (as measured in a vesicular stomatitis virus cytopathic assay system) 14 times greater than the currently available treatment using IFN-β 1b (9) . In the current study, Vero E6 cells were treated with concentrations (5,000 to 500,000 IU/mL) of IFN-β 1a either 24 h before or 1 h after inoculation with the SARS-CoV (multiplicity of infection 0.1 PFU/cell), and monitored for cytopathic effect and production of infectious SARS-CoV at 24, 48, and 72 h postinfection. Production of infectious SARS-CoV was potently inhibited (>99.5% or 2.00 log 10 PFU/mL) at 24 h postinfection by pretreatment of Vero E6 cells with IFN-β 1a at all concentrations tested (Figure 1 ).	./cache/cord-343273-zaaraiy7.txt	./txt/cord-343273-zaaraiy7.txt